Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ FailurePharmacology Published on 2020-11-102022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] activity acute lung injury acute respiratory distress adverse event AEs Affect Alpha Anti-inflammatory anti-inflammatory agents ARDS Cancer clinical Clinical course Clinical practice clinical study Compliance complications coronavirus disease COVID-19 COVID-19 patient Cytokine release syndrome dose-dependent dose-escalation double-blind evaluate examined exhibited failure GRADE growth factor healthy histopathological examination Human ICH include Inflammatory cytokine ingredient interleukin-6 intravenous Liver damage Model mortality rate mouse multi-organ dysfunction multi-organ failure Necrosis New niacinamide Patient patients phosphate placebo-controlled platform Pneumonia potent Preclinical Prevent profile Protective Pulmonary edema Randomized reduce respiratory response Riboflavin SAEs Safety safety profile Sepsis Serious Adverse Event Shock show Standard statistical analysis subject subjects survival syndrome Tolerability Treatment was performed [DOI] 10.3389/fphar.2020.594321 PMC 바로가기 [Article Type] Pharmacology
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysisMeta-Analysis Published on 2020-11-052022-10-04 Journal: Clinical microbiology and infection : the official [Category] MERS, SARS, 임상, 진단, [키워드] 95%CI adjusted adjusted RR adverse event approach association certainty of evidence citation Cohort cohort study cohorts concerning Controlled COVID-19 COVID-19 patients COVID-19 severity Daily death did not reduce Efficacy elevated eligibility criteria eligible evaluate evaluated Evidence examined FIVE Google higher risk hospitalized COVID-19 patients IL-6 IL-6 receptor Infection interleukin-6 lower mortality mechanical ventilation Meta-analysis moderate Mortality Multiorgan objective observational study observé Other OVID participant Patient patients Placebo Randomized controlled trial RCT RCTs reduce Result risk risk of bia Risk of bias risk ratio RRs severe coronavirus disease Standard of care syndrome systematic review Tocilizumab Toxicity treat Treatment Web of Science while [DOI] 10.1016/j.cmi.2020.10.036 PMC 바로가기 [Article Type] Meta-Analysis
Absolute Eosinophil Count Predicts Intensive Care Unit Transfer Among Elderly COVID-19 Patients From General Isolation WardsMedicine Published on 2020-11-042022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 95% CI Admission AEC age C-reactive protein Care caused Clinical characteristics conducted coronavirus disease count COVID-19 COVID-19 patient CRP cut-off value cytokine death elderly Elderly patient eosinophil eosinophils ferritin ferritin levels global pandemic groups Health help ICU IL-10 IL-6 IL-8 IMPROVE increased risk inflammation marker intensive care intensive care unit interleukin-6 Isolation Lymphocyte count marker Multivariate analysis neutrophil count Odds ratio Older outcomes predict prediction Predictive receptor Retrospective study sensitivity severity significantly higher specificity transfer tumor necrosis factor-α ward with COVID-19 [DOI] 10.3389/fmed.2020.585222 PMC 바로가기 [Article Type] Medicine
Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions병원 내 COVID-19 사망률 예측인자: 연령, 성별 및 건강 상태에 따른 차이를 탐색하는 포괄적인 체계적인 검토 및 메타 분석Research Article Published on 2020-11-032022-08-13 Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, [키워드] addition age albumin ALT applied AST Bilirubin C-reactive protein cardiac troponin Cardiac troponin I clinical condition clinical conditions Comorbidities Comorbidity Concentration conditions conducted confirmed COVID-19 patients COVID-19 COVID-19 mortality COVID-19 patient creatinine Critical database deaths diabete diabetes Dyspnoea effect size Factor ferritin followed by Haemoglobin Health health condition heterogeneity hospital hypertension In-hospital in-hospital mortality increased mortality interleukin-6 Kidney disease laboratory parameter Laboratory parameters LDH malignancy meta-analyses Meta-analysis meta-regression Mortality nitrogen obesity objective Odds ratio older patient older patients Patient patients Platelet Platelet count populations predictor predictors prognostic effect pulmonary disease random-effects meta-analyses registration number Result risk Sex smoking Subgroup analyses subgroup analysis systematic review the mean the MEDLINE total bilirubin troponin I urea urea nitrogen variable Web of Science [DOI] 10.1371/journal.pone.0241742 PMC 바로가기 [Article Type] Research Article
Clinical characteristics of asymptomatic carriers of novel coronavirus disease 2019: A multi-center study in Jiangsu ProvinceResearch Article Published on 2020-11-022022-10-28 Journal: Virulence [Category] COVID-19, MERS, [키워드] Admission age analyses Analysis Asymptomatic carrier Asymptomatic carriers asymptomatic individual Blood C-reactive protein CD3+ CD4+ CD8+ Cell Characteristics clinical Clinical characteristics Clinical practice conducted correlation COVID-19 critical cases Cutoff cytokine determine diagnostic Disease progression disease severity disease severity of COVID-19 enrolled eosinophil erythrocyte sedimentation rate evaluated female group immune response Inflammatory marker interleukin-6 investigated Jiangsu Laboratory laboratory parameter leukocyte lymphocyte male mild cases Multiple regression novel coronavirus disease Novel coronavirus disease-19 Platelet predictor receiver operating characteristic SARS-CoV-2 SARS-CoV-2-infected individual severe acute respiratory syndrome coronavirus 2 severity significantly Spearman Spread subject subset T lymphocyte thought virus virus transmission with COVID-19 [DOI] 10.1080/21505594.2020.1840122 PMC 바로가기 [Article Type] Research Article
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic reviewVirology Published on 2020-11-022022-10-28 Journal: PeerJ [Category] COVID-19, [키워드] 95% CI absence Analysis antiviral therapy case-control study cause characterized clinical study clinical trials Combined COVID-19 COVID-19 mortality Critical cytokine drug dysregulated immune response Effect effective Efficacy Evaluating Evidence fatality group hypercytokinemia IL-6 IL-6 inhibitor include interleukin-6 lack lower mortality lymphocytopenia Mortality mortality rate Odds ratio pathophysiological performed positive pro-inflammatory cytokine producing quantitative synthesis random effect Randomized randomized control trial reducing Research Result SARS-CoV-2 severe COVID-19 Standard of care suppress systematic analysis systematic review TCZ the disease Tocilizumab treat Treatment Trial [DOI] 10.7717/peerj.10322 PMC 바로가기 [Article Type] Virology
Interleukin-6 in Covid-19: A systematic review and meta-analysis코로나19의 인터루킨-6: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2020-11-012022-09-11 Journal: Reviews in Medical Virology [Category] SARS, 바이오마커, [키워드] 95% confidence interval 95%CI activate authors clinical outcomes Concentration COVID-19 cytokine Cytokine storm demonstrated disease dysregulated elevated eligible Evidence exploratory study for inclusion Grey literature host immune responses host response ICU admission IL-6 IL-6 level IL-6 levels IL6 immune responses Immunological response inhibition interleukin interleukin-6 Intervention management Meta-analysis moderate Patient random effect required Risk of bias SARS-CoV-2 searched Sensitivity analyses sensitivity analysis significantly suggested systematic review Therapeutics Tocilizumab were assessed [DOI] 10.1002/rmv.2141 PMC 바로가기 [Article Type] Meta-Analysis
Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient임산부의 중증급성호흡기증후군 코로나바이러스 2 치료에 대한 치료 옵션Review Published on 2020-11-012022-09-11 Journal: American journal of obstetrics & gynecology MFM [Category] SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addressed anticoagulation Case series case sery Chloroquine Complication Contact contact with convalescent convalescent plasma coronavirus Corticosteroids exclusion healthcare Hydroxychloroquine Inclusion Infection inhibitors interleukin interleukin-6 interleukin-6 inhibitors Lopinavir Lopinavir-ritonavir pandemic Patient plethora pregnant pregnant patient pregnant patients pregnant population Prevent randomized control trial Randomized control trials Remdesivir respiratory Ritonavir severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Side effect therapeutic option therapeutic options treat Treatment Trial [DOI] 10.1016/j.ajogmf.2020.100224 PMC 바로가기 [Article Type] Review
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimabCOVID-19의 내피 손상 및 혈전성 미세혈관병증: 렉틴 경로 억제제 나르소플리맙으로 치료Article Published on 2020-11-012022-09-11 Journal: Immunobiology [Category] SARS, 진단, 치료법, [키워드] activate Activation acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome Adverse drug reaction Adverse drug reactions anticoagulant effects ARDS Arterial thrombosis Autopsies baseline bind C-reactive protein C-reactive protein (CRP circulating compassionate use complement Complement activation complications Continuous Positive Airway Pressure control group Coronavirus-2 COVID-19 COVID-19 patient CPAP CRP during treatment effective Endothelial cell endothelial cell damage endothelial damage endothelial injury enzyme human immunoglobulin IgG4 IL-6 IL-8 Immunoglobulin Inflammation inhibit inhibitor Injury interleukin interleukin-6 interleukin-8 intubation Lactate lactate dehydrogenase LDH lectin lectin pathway life-threatening Lung injury mannan MASP-2 monoclonal antibody Mortality Narsoplimab nucleocapsid protein pathogenic Patient positive airway pressure reducing reduction reported respiratory respiratory distress Respiratory distress syndrome resulting retrospective SARS-CoV-2 Serine serine protease serum Serum IL-6 Serum level serum levels Severe acute respiratory syndrome severe acute respiratory syndrome-associated coronavirus-2 significantly higher survived sustained syndrome thrombosis thrombotic thrombotic event Thrombotic events thrombotic risk treat Treatment treatment for COVID-19 was used were assessed were used [DOI] 10.1016/j.imbio.2020.152001 PMC 바로가기 [Article Type] Article
Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6토실리주맙 이후 초기에 높은 수준의 IL-6은 COVID-19 폐렴에서 생존자와 비생존자를 구별합니다: IL-6의 더 깊은 표적화에 대한 가능한 징후Article Published on 2020-11-012022-09-11 Journal: Journal of medical virology [Category] 바이오마커, 진단, [키워드] 48 hour 48 hours 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected All the patient all the patients baseline blocking cause choice Comparisons coronavirus COVID-19 COVID-19 patients COVID-19 pneumonia cytokine cytokine release storm Cytokine storm discharged dose elevated get out hyperinflammatory state IL-6 interleukin interleukin-6 intravenously Laboratory material nonsurvivor nonsurvivors not different outcomes Patient patients died performed Pneumonia Predictive respiratory serious COVID-19 serum Serum IL-6 Serum level serum levels severe acute respiratory syndrome Coronavirus significantly significantly higher Support survivor tested the cytokine storm Tocilizumab two group two groups [DOI] 10.1002/jmv.26149 PMC 바로가기 [Article Type] Article